You are here

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

New Research Abstracts Scheduled for Presentation on Daxor’s BVA-100®

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 48th Congress at the San Diego Convention Center in San Diego, CA from February 17-19th, 2019. Research from the University of Hawaii John A. Burns School of Medicine relating to the use of Daxor’s BVA-100 blood volume analyzer in Critical Care use is scheduled to be presented.

“Peer-reviewed studies including a randomized control trial have proven that optimization of intravascular blood volume improves outcomes, length of stay, and can reduce mortality by up to 66% versus conventional therapy in complex critically-ill patients. We look forward to sharing with leaders new data and how the BVA-100® (Blood Volume Analyzer) can help guide fluid management to enhance treatment plans and individualize care,” said Michael Feldschuh, CEO of Daxor Corporation. The company will be exhibiting at Booth #926.

About Daxor Corporation

Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner
CORE IR
561-479-8566
brets@coreir.com

Wednesday, February 13, 2019 - 08:30